BRPI0914927B8 - composto, composição farmacêutica e uso de um composto - Google Patents

composto, composição farmacêutica e uso de um composto

Info

Publication number
BRPI0914927B8
BRPI0914927B8 BRPI0914927A BRPI0914927A BRPI0914927B8 BR PI0914927 B8 BRPI0914927 B8 BR PI0914927B8 BR PI0914927 A BRPI0914927 A BR PI0914927A BR PI0914927 A BRPI0914927 A BR PI0914927A BR PI0914927 B8 BRPI0914927 B8 BR PI0914927B8
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
medicines
cancer
function
Prior art date
Application number
BRPI0914927A
Other languages
English (en)
Inventor
Christophe Barlaam Bernard
David Jones Clifford
Michael Foote Kevin
Ple Patrick
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0914927A2 publication Critical patent/BRPI0914927A2/pt
Publication of BRPI0914927B1 publication Critical patent/BRPI0914927B1/pt
Publication of BRPI0914927B8 publication Critical patent/BRPI0914927B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

composto, composição farmacêutica, métodos para inibir a função de fak e de tratamento de um câncer, uso de um composto, e, processo para preparar um composto. a presente invenção diz respeito a compostos que inibem a função cinase de adesão focal, processos para a sua preparação, composições farmacêuticas que as contenham como o ingrediente ativo, ao seu uso como medicamentos e ao seu uso na fabricação de medicamentos para o uso no tratamento em animais de sangue quente tais como seres humanos de doenças tais como câncer.
BRPI0914927A 2008-06-17 2009-06-15 composto, composição farmacêutica e uso de um composto BRPI0914927B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7305508P 2008-06-17 2008-06-17
US61/073055 2008-06-17
PCT/GB2009/050675 WO2009153589A1 (en) 2008-06-17 2009-06-15 Pyridine compounds

Publications (3)

Publication Number Publication Date
BRPI0914927A2 BRPI0914927A2 (pt) 2017-06-20
BRPI0914927B1 BRPI0914927B1 (pt) 2020-10-06
BRPI0914927B8 true BRPI0914927B8 (pt) 2021-05-25

Family

ID=40896110

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0914927A BRPI0914927B8 (pt) 2008-06-17 2009-06-15 composto, composição farmacêutica e uso de um composto

Country Status (17)

Country Link
US (1) US8569298B2 (pt)
EP (1) EP2303861B1 (pt)
JP (1) JP5551689B2 (pt)
KR (1) KR101695501B1 (pt)
CN (1) CN102124000B (pt)
AU (1) AU2009261764B2 (pt)
BR (1) BRPI0914927B8 (pt)
CA (1) CA2726508C (pt)
CR (1) CR11854A (pt)
DO (1) DOP2010000390A (pt)
EA (1) EA020807B1 (pt)
EC (1) ECSP10010695A (pt)
ES (1) ES2472323T3 (pt)
IL (1) IL209727A0 (pt)
MX (1) MX2010014057A (pt)
WO (1) WO2009153589A1 (pt)
ZA (1) ZA201100388B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3384482B2 (ja) 1997-03-18 2003-03-10 本田技研工業株式会社 ピストンリング供給装置
US20140155410A1 (en) * 2008-10-27 2014-06-05 Glaxosmithkline Llc Pyrazolylaminopyridines as inhibitors of fak
JO3067B1 (ar) * 2008-10-27 2017-03-15 Glaxosmithkline Llc بيرميدينات بيرازولو امينو كمثبطات ل fak
WO2010068947A2 (en) * 2008-12-12 2010-06-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Nuclear export inhibitors of topoisomerase ii alpha
HUE034911T2 (hu) 2009-07-27 2018-03-28 Gilead Sciences Inc Fúzionált heterociklusos vegyületek mint ioncsatorna modulátorok
BR112012029647A2 (pt) 2010-05-21 2016-08-02 Chemilia Ab novos derivados de pirimidinas
CA2803004A1 (en) 2010-06-29 2012-01-12 Poniard Pharmaceuticals, Inc. Oral formulations of kinase inhibitors
CN103168037A (zh) * 2010-06-30 2013-06-19 博尼亚德医药品股份有限公司 激酶抑制剂的合成和用途
EP2588197B1 (en) 2010-07-02 2014-11-05 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
AU2012209100A1 (en) * 2011-01-26 2013-08-01 Board Of Regents The University Of Texas System Combinations
WO2012110773A1 (en) 2011-02-17 2012-08-23 Cancer Therapeutics Crc Pty Limited Fak inhibitors
DK2675794T3 (da) 2011-02-17 2019-05-06 Cancer Therapeutics Crc Pty Ltd Selektive fak-inhibitorer
MX2013010898A (es) 2011-03-24 2013-12-06 Chemilia Ab Novedoso derivados de la pirimidina.
WO2012154760A1 (en) 2011-05-10 2012-11-15 Gilead Sciences, Inc. Fused heterocyclic compounds as sodium channel modulators
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
NO3175985T3 (pt) 2011-07-01 2018-04-28
CN104302640A (zh) 2012-03-16 2015-01-21 埃克希金医药品有限公司 3,5-二氨基吡唑激酶抑制剂
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
AP2016009605A0 (en) * 2014-06-17 2016-12-31 Pfizer Substituted dihydroisoquinolinone compounds
US9442005B2 (en) * 2014-07-30 2016-09-13 Corning Optical Communications LLC Non-contact methods of measuring insertion loss in optical fiber connectors
MY191736A (en) 2014-12-23 2022-07-13 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
GB201510010D0 (en) 2015-06-09 2015-07-22 King S College London PDD and BPD compounds
EA201890161A1 (ru) 2015-06-29 2018-06-29 Верастэм, Инк. Терапевтические композиции, комбинации и способы применения
US20180339985A1 (en) 2015-08-21 2018-11-29 Femtogenix Limited Pdd compounds
GB201514928D0 (en) 2015-08-21 2015-10-07 King S College London PDD compounds
EP3758491A1 (en) 2018-02-28 2021-01-06 Basf Se Use of pyrazole propargyl ethers as nitrification inhibitors
JP7444780B2 (ja) 2018-02-28 2024-03-06 ビーエーエスエフ ソシエタス・ヨーロピア 硝化阻害剤としてのｎ－官能化アルコキシピラゾール化合物の使用
AU2019236402A1 (en) 2018-03-12 2020-10-01 Assistance Publique-Hôpitaux De Paris (Aphp) Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers
CN108912095B (zh) * 2018-08-09 2019-08-20 广州安岩仁医药科技有限公司 苯并咪唑类化合物及其制备方法和应用
JP2022525186A (ja) 2019-03-15 2022-05-11 ザ ジェネラル ホスピタル コーポレイション Ｔｅａｄ転写因子新規小分子阻害剤
US12590298B2 (en) 2019-10-18 2026-03-31 The Regents Of The University Of California Ex vivo tumor angiogenesis model
US11884647B2 (en) 2019-10-18 2024-01-30 The Regents Of The University Of California Compounds and methods for targeting pathogenic blood vessels
AR125955A1 (es) 2021-05-21 2023-08-30 Basf Se Uso de un compuesto de alcoxi pirazol n-funcionalizado como inhibidor de nitrificación

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
DE10336184A1 (de) 2003-08-07 2005-02-24 Bayer Materialscience Ag Neue Katalysatoren für die selektive Isocyanatdimerisierung
ATE542801T1 (de) * 2003-08-15 2012-02-15 Novartis Ag Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine
EP1765461A1 (en) 2004-06-21 2007-03-28 Pharmacia & Upjohn Company LLC Pyk2 inhibitors for stimulation of osteoblast function
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
GB0419160D0 (en) 2004-08-27 2004-09-29 Novartis Ag Organic compounds
US8211929B2 (en) 2004-12-30 2012-07-03 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
CA2632149C (en) * 2005-12-01 2011-11-15 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
EP1966207A2 (en) 2005-12-21 2008-09-10 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
JP5208123B2 (ja) 2006-12-08 2013-06-12 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
EP2134689B1 (en) * 2007-03-16 2014-04-23 The Scripps Research Institute Inhibitors of focal adhesion kinase
JP2010533729A (ja) * 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
WO2009105498A1 (en) * 2008-02-19 2009-08-27 Smithkline Beecham Corporation Anilinopyridines as inhibitors of fak

Also Published As

Publication number Publication date
EA201100032A1 (ru) 2012-01-30
JP5551689B2 (ja) 2014-07-16
DOP2010000390A (es) 2011-01-15
AU2009261764B2 (en) 2013-01-10
EP2303861B1 (en) 2014-04-23
BRPI0914927B1 (pt) 2020-10-06
ZA201100388B (en) 2011-10-26
HK1155170A1 (en) 2012-05-11
CA2726508A1 (en) 2009-12-23
IL209727A0 (en) 2011-02-28
ECSP10010695A (es) 2011-01-31
EP2303861A1 (en) 2011-04-06
JP2011524411A (ja) 2011-09-01
KR20110023884A (ko) 2011-03-08
CN102124000B (zh) 2014-09-17
MX2010014057A (es) 2011-03-21
CN102124000A (zh) 2011-07-13
AU2009261764A1 (en) 2009-12-23
WO2009153589A1 (en) 2009-12-23
US20110166139A1 (en) 2011-07-07
ES2472323T3 (es) 2014-06-30
EA020807B1 (ru) 2015-01-30
US8569298B2 (en) 2013-10-29
CR11854A (es) 2011-02-25
BRPI0914927A2 (pt) 2017-06-20
CA2726508C (en) 2016-06-07
KR101695501B1 (ko) 2017-01-11

Similar Documents

Publication Publication Date Title
MX2010014057A (es) Compuestos de piridina.
BRPI0805826A2 (pt) compostos espiro-substituìdos como inibidores de angiogênese, método de produção de um composto, composição farmacêutica e métodos de tratamento
BR112012009376B8 (pt) composição farmacêutica sólida compreendendo um inibidor de sglt-2 e sua forma de dosagem farmacêutica
BRPI0507790A (pt) composto de pirazolina substituìda, processo para a sua manufatura, medicamentos e seus usos
BRPI0808764B8 (pt) compostos espiro-substituídos como inibidores de angiogênese seu processo de produção e composição farmacêutica
BRPI0514691A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, composição farmacêutica, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
TW200716623A (en) Chemical compounds
BRPI0912475B8 (pt) compostos como inibidores de quinase, método para produção dos ditos compostos e composição farmacêutica
BR112016002496A2 (pt) composto de fórmula i, composição farmacêutica, método para inibição de kdm1a, método para tratamento de uma doença mediada por globina, método para atingir um efeito em um paciente, e, método para inibir pelo menos uma função de kdm1a
BR112013022789A2 (pt) composições farmacêuticas que compreendem metformina e um inibidor dpp-4 ou um inibidor sglt-2
BRPI0518126A (pt) composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito inibitório de b-raf e um efeito anti-cáncer em um animal de sangue quente, e para tratar uma doença ou condição
BR112012010270A2 (pt) mentisulfonilmetano (msm) para tratamento de micro-organismos resistentes a fármaco
BR112015014372A8 (pt) inibidores de autotaxina, seus usos, e composição e combinação farmacêuticas".
BR112013026834A2 (pt) composto, composição farmacêutica, produto farmacêutico de combinação, uso de um composto, e, método para tratar doenças ou condições e para inibir um bromodomínio
CY1111203T1 (el) 4-ανιλινοκινολινο-3-καρβοξαμιδια ως αναστολεις κινασης csf-1r
AR128459A2 (es) Composición farmacéutica sólida comprimida por rodillo y el proceso para su fabricación
BRPI0512796A (pt) composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito inibitório de b-raf, e um efeito anticáncer em um animal de sangue quente, e para tratar uma doença
ATE487720T1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
BRPI0507801A (pt) compostos de azetidina substituìda, processo para a preparação de compostos de azetidina substituìda, medicamento e uso de pelo menos um composto de azetidina substituìda
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
RU2012157473A (ru) Способ выявления или лечения реакции "трансплантат против хозяина"
TW200745043A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
BR112014006223A2 (pt) 6-substituídas-3-(quinolin-6-iltio)-[1,2,4-triazol[4,3-a] piradinas como tirosina quinase c-met
BRPI0610090A2 (pt) terapia de combinaÇço compreendendo diaril urÉias para tratar doenÇas
CL2021001944A1 (es) Derivados de aminoácidos para el tratamiento de enfermedades inflamatorias

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/06/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF